Bard Infuse-A-Port Lawsuit Filed After Pulmonary Embolism, Catheter Fragments Found in Heart

Pieces of the fractured Bard Infuse-A-Port remain in the plaintiffs heart, which puts her at risk of severe injuries in the future.

A Maryland woman who received a Bard Infuse-A-Port to facilitate her chemotherapy treatment has filed a lawsuit indicating that the port catheter fractured, sending fragments into her heart and causing her to suffer a pulmonary embolism.

The complaint (PDF) was brought by Johanna Randow in Arizona federal court on September 19, pursuing product liability claims against C.R. Bard and Bard Access Systems, Inc. as defendants.

The Bard Infuse-A-Port is a vascular access device that is part of the company’s PowerPort product line, which is implanted below the skin to provide a port that allows the easy delivery of medications to a patient’s blood stream. It consists mainly of an injection port, where the needle is inserted to deliver medications, and a polyurethane catheter tube which carries the drug into the blood vessel.

Unlike other implanted ports, such as Port-a-cath or Mediport, the Bard PowerPort is marketed as a special type of port catheter, which is intended to withstand higher injection pressures. However, Randow’s complaint now joins a growing number of Bard PowerPort lawsuits, alleging that the catheter tube is prone to fracture and rupture, which can cause life-threatening infections, pulmonary embolism, deep vein thrombosis and other complications.

Bard Port Catheter Lawsuit

Did you suffer problems form a Bard Powerport?

Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.

Learn More About this Lawsuit See If You Qualify For Compensation

Randow’s lawsuit indicates she underwent placement of a Bard Infuse-A-Port implant in April 2018, in order to more easily receive drugs for chemotherapy. Due to device failure, she underwent revision surgery to have the device removed in July 2019.

However, more than two years later, in November 2021, Randow suffered a pulmonary embolism, and subsequent examinations determined that a portion of the fractured Infuse-A-Port catheter had broken off and traveled into her heart, causing the embolism.

One or more of the fragments still remain in Randow’s heart, putting her at substantial risk of future injury, the lawsuit indicates.

Randow claims Bard knew about the risk of problems with Infuse-A-Port products, had received reports of device Bard PowerPort fractures, failures and injuries, but refused to inform patients or the medical community about the potential risks.

“Defendants did not adequately warn Plaintiff or Plaintiff’s physicians of the true quantitative or qualitative risk of fracture, migration, perforation, thromboembolism or dislodgment associated with the Infuse-A-Port system,” Randow’s lawsuit states. “Rather than alter the design of their product to make it safer or warn physicians of the dangers associated with the Infuse-A-Port, the Defendants chose to continue their efforts to promote their defective product.”

September 2023 Bard PowerPort Lawsuit Update

With a growing number of similar claims being filed throughout the federal court system, each raising similar allegations that Bard failed disclose the potential chemo port risks, the U.S. Judicial Panel on Multidistrict Litigation (JPML) decided last month to consolidate all Bard port catheter lawsuits in the District of Arizona, where U.S. District Judge David Campbell was assigned to preside over coordinated pretrial procedures.

Each of the complaints involve injuries that allegedly resulted from a failure of a Bard port catheter, including migration of the device, infections, blood clots, deep vein thrombosis, perforations and other damage caused by a Bard PowerPort fracture.

As part of the management of the port catheter lawsuits, it is expected that Judge Campbell will coordinate discovery into common issues that impact all of the claims, and select a small group of representative cases that will be prepared for early trial dates, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation. However, if the manufacturer fails to negotiation Bard Port settlements following these MDL proceedings, each case may later be remanded back to the U.S. District Court where it was originally filed for a separate trial date in the future.

Find Out If You Qualify for Port Catheter Compensation


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024
Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024 (Posted 5 days ago)

With thousands of Bard hernia mesh lawsuits pending in the federal court system, a fourth bellwether trial will be held in the spring, involving allegations that defects with Bard 3DMax caused painful and permanent injuries.